This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Date:

November 13, 2024

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.

Source link

Phillip Lim Steps Down as Creative Director of 3.1 Phillip Lim

Nelly Furtado Says She Endured ‘Abusive Qualities' in Past Relationship

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Recent posts

Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds

How Tesla stock became a ‘Trump trade’ despite GOP climate skepticism

These 20 stocks have been the S&P 500’s biggest losers so far in 2024

Investors are bracing for higher-for-even-longer interest rates

Dollar General’s stock heads for record plunge after a triple miss for earnings

Earnings Watch: Walmart reports this week. Its ‘resilience’ will be tested amid signs of consumer slowdown, analyst says

Wall Street is going all-in on election betting markets. What you need to know.

This chart shows gold vs. the stock market since Bernanke’s famous helicopter drop speech

News Corp’s REA says $7.3 billion bid for Rightmove was rejected

After falling quarterly sales, Mattel says next year will be better

AMC’s theaters have their best weekend of 2024 thanks to ‘Inside Out 2’ — but its stock is falling

Airbnb is seeing ‘strong demand trends’ — with these caveats

Ulta Beauty’s same-store sales take a surprising turn, and retailer’s stock drops 8%

Record gold prices are in a ‘different world’ than silver and copper. Here’s why.

Oil prices lifted by report Iran may be planning another major strike on Israel

Related articles

Trump’s choice of Dr. Oz to oversee Medicare and Medicaid could be ‘devastating’ for millions of Americans

Buy gold after its pullbacks — because it may hit $3,000 in 2025

Bitcoin sits near record high. More good news for investors: It’s now less volatile.

RFK Jr. may start a food and drug ‘culture war.’ Investors are running for cover.

Here’s what bond and gold traders are signaling about Russia’s nuclear shift

Stock market ‘finally paying more attention to tariffs’ as a potential headwind

Investors are bracing for higher-for-even-longer interest rates

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Company

Follow us